| scholarly article | Q13442814 |
| P356 | DOI | 10.1086/321811 |
| P698 | PubMed publication ID | 11418877 |
| P50 | author | Michael A. Pfaller | Q62070176 |
| Raymond Wiblin | Q71492763 | ||
| P2093 | author name string | R P Wenzel | |
| M G Rinaldi | |||
| J E Edwards | |||
| W R Jarvis | |||
| J M Soucie | |||
| L Saiman | |||
| H M Blumberg | |||
| J E Patterson | |||
| M S Rangel-Frausto | |||
| National Epidemiology of Mycoses Survey(NEMIS) Study Group | |||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | epidemiology | Q133805 |
| intensive care unit | Q5094647 | ||
| P304 | page(s) | 177-186 | |
| P577 | publication date | 2001-06-20 | |
| P1433 | published in | Clinical Infectious Diseases | Q5133764 |
| P1476 | title | Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. The National Epidemiology of Mycosis Survey | |
| P478 | volume | 33 |
| Q37115815 | A 10-year survey of antifungal susceptibility of candidemia isolates from intensive care unit patients in Greece |
| Q38652609 | A Mortality Study for ICU Patients using Bursty Medical Events |
| Q33378325 | A first Portuguese epidemiological survey of fungaemia in a university hospital |
| Q51798976 | A multicenter trial to compare blood culture with polymerase chain reaction in severe human sepsis. |
| Q79733359 | A prospective epidemiological survey of candidaemia in Sweden |
| Q37252122 | A single-centre 10-year experience with Candida bloodstream infections |
| Q38165883 | An Italian consensus for invasive candidiasis management (ITALIC). |
| Q89284760 | Analyzing candidemia guideline adherence identifies opportunities for antifungal stewardship |
| Q35908313 | Anidulafungin compared with fluconazole in severely ill patients with candidemia and other forms of invasive candidiasis: support for the 2009 IDSA treatment guidelines for candidiasis |
| Q41645558 | Antibiotic overuse as a risk factor for candidemia in an Indian pediatric ICU. |
| Q37608784 | Antifungal Susceptibility and Risk Factors in Patients with Candidemia |
| Q24244555 | Antifungal agents for preventing fungal infections in non-neutropenic critically ill patients |
| Q24246969 | Antifungal agents for preventing fungal infections in non-neutropenic critically-ill patients |
| Q35775400 | Antifungal de-escalation was not associated with adverse outcome in critically ill patients treated for invasive candidiasis: post hoc analyses of the AmarCAND2 study data |
| Q37624714 | Antifungal prophylaxis and pre-emptive therapy |
| Q39445046 | Antifungal susceptibility of bloodstream Candida isolates in Sfax hospital: Tunisia |
| Q49425859 | Application of Culture-Independent Rapid Diagnostic Tests in the Management of Invasive Candidiasis and Cryptococcosis |
| Q36641985 | Bench-to-bedside review: Candida infections in the intensive care unit |
| Q21194915 | Bench-to-bedside review: therapeutic management of invasive candidiasis in the intensive care unit |
| Q34453558 | Biofilm production by isolates of Candida species recovered from nonneutropenic patients: comparison of bloodstream isolates with isolates from other sources |
| Q34237335 | Canadian clinical practice guidelines for invasive candidiasis in adults |
| Q48163282 | Candida Species Biofilms' Antifungal Resistance. |
| Q92921364 | Candida albicans Antifungal Resistance and Tolerance in Bloodstream Infections: The Triad Yeast-Host-Antifungal |
| Q37373083 | Candida albicans specializations for iron homeostasis: from commensalism to virulence |
| Q81978637 | Candida bloodstream infections in hemodialysis recipients |
| Q34529179 | Candida bloodstream infections: comparison of species distributions and antifungal resistance patterns in community-onset and nosocomial isolates in the SENTRY Antimicrobial Surveillance Program, 2008-2009 |
| Q37624708 | Candida colonization and candiduria in critically ill patients in the intensive care unit |
| Q46971625 | Candidemia and candiduria in critically ill patients admitted to intensive care units in France: incidence, molecular diversity, management and outcome |
| Q34488253 | Candidemia in Finland, 1995-1999. |
| Q92506877 | Candidemia in critically ill immunocompromised patients: report of a retrospective multicenter cohort study |
| Q47619707 | Candidemia in critically ill patients: difference of outcome between medical and surgical patients |
| Q80382945 | Candidemia in immunocompromised and immunocompetent critically ill patients: a prospective comparative study |
| Q37443115 | Candidemia on presentation to the hospital: development and validation of a risk score |
| Q73413836 | Candiduria in critically ill patients admitted to intensive care medical units |
| Q34528210 | Catheter-related Candida bloodstream infection in intensive care unit patients: a subgroup analysis of the China-SCAN study |
| Q24195090 | Central venous catheter (CVC) removal for adult patients with candidaemia |
| Q26471135 | Central venous catheter (CVC) removal for patients of all ages with candidaemia |
| Q34505582 | Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America |
| Q54218643 | Clinical Significance of Candida in an Intraoperative Peritoneal Specimen with Perforation Peritonitis: An Institutional Perspective. |
| Q37624699 | Clinical aspects of invasive candidiasis in the surgical patient |
| Q44866472 | Clinical factors associated with fluconazole resistance and short-term survival in patients with Candida bloodstream infection |
| Q34936576 | Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. |
| Q36348507 | Clinico-microbiological study of candidemia in a tertiary care hospital of southern part of India |
| Q42561331 | Comparison of results of voriconazole disk diffusion testing for Candida species with results from a central reference laboratory in the ARTEMIS global antifungal surveillance program. |
| Q37279900 | Cost-effectiveness of micafungin as an alternative to fluconazole empiric treatment of suspected ICU-acquired candidemia among patients with sepsis: a model simulation |
| Q37327099 | Critical overview of clinical guidelines relating to invasive fungal infections |
| Q35038450 | Deeply invasive candidiasis |
| Q24530412 | Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality |
| Q61757070 | Diagnose und Therapie der Sepsis |
| Q44754456 | Diagnosis and therapy of sepsis |
| Q35574038 | Diagnosis of invasive candidiasis in the ICU. |
| Q33899912 | Diagnostic usefulness of differential time to positivity for catheter-related candidemia |
| Q34465297 | EMPIRICUS micafungin versus placebo during nosocomial sepsis in Candida multi-colonized ICU patients with multiple organ failures: study protocol for a randomized controlled trial |
| Q34574154 | Economic considerations of antifungal prophylaxis in patients undergoing surgical procedures |
| Q33559164 | Effect of antifungal therapy timing on mortality in cancer patients with candidemia |
| Q33875368 | Effective photosensitization and selectivity in vivo of Candida Albicans by meso-tetra (N-methyl-4-pyridyl) porphine tetra tosylate |
| Q34708081 | Efficacy of parenteral nutrition supplemented with glutamine dipeptide to decrease hospital infections in critically ill surgical patients |
| Q75241319 | Emerging opportunistic fungal infections: where are we heading? |
| Q26852351 | Empiric/pre-emptive anti-Candida therapy in non-neutropenic ICU patients |
| Q40458611 | Epidemiology and antifungal susceptibility of Candida species isolated from blood: results of a 2-year multicentre study in Spain. |
| Q35089772 | Epidemiology and treatment approaches in management of invasive fungal infections |
| Q34273626 | Epidemiology of Candida species infections in critically ill non-immunosuppressed patients |
| Q40524039 | Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. |
| Q89689856 | Epidemiology of candidemia and impact of infectious disease consultation on survival and care |
| Q35073043 | Epidemiology of candidemia in Brazil: a nationwide sentinel surveillance of candidemia in eleven medical centers |
| Q37327113 | Epidemiology of candidemia in intensive care units |
| Q33183542 | Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study. |
| Q29616758 | Epidemiology of invasive candidiasis: a persistent public health problem |
| Q37624691 | Epidemiology, incidence and risk factors for invasive candidiasis in high-risk patients |
| Q92504604 | Epidemiology, species distribution, antifungal susceptibility and mortality risk factors of candidemia among critically ill patients: a retrospective study from 2011 to 2017 in a teaching hospital in China |
| Q47094301 | Evaluation of Candida Scoring Systems to Predict Early Candidemia: A Prospective and Observational Study at a Tertiary Care Hospital, Uttarakhand |
| Q43219915 | Factors related to survival and treatment success in invasive candidiasis or candidemia: a pooled analysis of two large, prospective, micafungin trials. |
| Q81898469 | Fungal colonization and/or infection in non-neutropenic critically ill patients: results of the EPCAN observational study |
| Q36206568 | Fungal infections: their diagnosis and treatment in transplant recipients |
| Q37155657 | Gene Expression and Identification Related to Fluconazole Resistance of Candida glabrata Strains |
| Q36789279 | Herpes Simplex Virus (HSV) Modulation of Staphylococcus aureus and Candida albicans Initiation of HeLa 299 Cell-Associated Biofilm |
| Q37734169 | Historical trends in the epidemiology of candidaemia: analysis of an 11-year period in a tertiary care hospital in Brazil |
| Q38560299 | ICU-acquired candidemia within selective digestive decontamination studies: a meta-analysis |
| Q35125400 | Impact of fluconazole prophylaxis on cortisol levels in critically ill surgical patients |
| Q36642052 | Impact of invasive fungal infection on outcomes of severe sepsis: a multicenter matched cohort study in critically ill surgical patients |
| Q36128249 | Impact of selective decontamination of the digestive tract on fungal carriage and infection: systematic review of randomized controlled trials |
| Q35689372 | Improved antibiotic-impregnated catheters with extended-spectrum activity against resistant bacteria and fungi |
| Q34194192 | Increasing incidence of candidemia: results from a 20-year nationwide study in Iceland |
| Q44944401 | Indications for antifungal treatment in intensive care unit patients |
| Q46260578 | Influence of phosphatidylserine and phosphatidylethanolamine on farnesol tolerance in Candida albicans |
| Q38734907 | Integrating Time-Varying and Ecological Exposures into Multivariate Analyses of Hospital-Acquired Infection Risk Factors: A Review and Demonstration |
| Q40449192 | Integrin Cross-Talk Regulates the Human Neutrophil Response to Fungal β-Glucan in the Context of the Extracellular Matrix: A Prominent Role for VLA3 in the Antifungal Response. |
| Q46784358 | International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. |
| Q35768705 | Intravenous Catheter-Associated Candidemia due to Candida membranaefaciens: The First Iranian Case |
| Q41654518 | Invasive Candida infections in patients of a medical intensive care unit: attempt of improving diagnosis by quantifying the colonization |
| Q53697489 | Invasive Candidiasis in Critically Ill Patients: A Prospective Cohort Study in Two Tertiary Care Centers. |
| Q22305429 | Invasive candidiasis as a cause of sepsis in the critically ill patient |
| Q34452343 | Invasive candidiasis in critical care setting, updated recommendations from "Invasive Fungal Infections-Clinical Forum", Iran |
| Q35010671 | Invasive candidiasis in non-hematological patients |
| Q37514625 | Invasive candidiasis: an overview from Taiwan |
| Q30251428 | Invasive candidiasis: from mycobiome to infection, therapy, and prevention |
| Q36540976 | Invasive fungal infections in critically ill patients: different therapeutic options and a uniform strategy |
| Q37373771 | Invasive fungal infections in patients with cancer in the Intensive Care Unit |
| Q38180287 | Invasive fungal infections in the ICU: how to approach, how to treat. |
| Q37481878 | Is incidental recovery of yeast from enteric pathogen stool cultures obtained from hospitalized patients clinically significant? |
| Q37612914 | Low Caspofungin Exposure in Patients in Intensive Care Units. |
| Q35585233 | Management of Severe Sepsis: Integration of Multiple Pharmacologic Interventions |
| Q51177304 | Management of candidemia and invasive candidiasis |
| Q37313058 | Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: Part I. Epidemiology and diagnosis. |
| Q35904821 | Management of invasive candidiasis in critically ill patients |
| Q43082447 | Management of invasive candidiasis in the intensive care unit |
| Q41912063 | Mannose-binding lectin deficiency facilitates abdominal Candida infections in patients with secondary peritonitis |
| Q40643523 | Mechanism of intestinal-derived fungal sepsis by gliotoxin, a fungal metabolite |
| Q36749310 | Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting |
| Q37098160 | Multidisciplinary approach to the treatment of invasive fungal infections in adult patients. Prophylaxis, empirical, preemptive or targeted therapy, which is the best in the different hosts? |
| Q34489579 | Nationwide sentinel surveillance of bloodstream Candida infections in 40 tertiary care hospitals in Spain |
| Q35587111 | New approaches to the risk of Candida in the intensive care unit |
| Q49803837 | Non-Culture Diagnostics for Invasive Candidiasis: Promise and Unintended Consequences |
| Q35116820 | Non-albicans Candida is the most common cause of candidemia in pediatric cancer patients |
| Q56935049 | Nosocomial Candidemia: An Ounce of Prevention Is Better Than a Pound of Cure |
| Q33910250 | One year prospective survey of Candida bloodstream infections in Scotland. |
| Q37873399 | Opportunistic invasive fungal pathogen Macrophomina phaseolina prognosis from immunocompromised humans to potential mitogenic RBL with an exceptional and novel antitumor and cytotoxic effect. |
| Q26774692 | Optimizing Outcomes in Immunocompromised Hosts: Understanding the Role of Immunotherapy in Invasive Fungal Diseases |
| Q81288270 | Oral nystatin as antifungal prophylaxis in critically ill patients: an old SDD tool to be renewed? |
| Q37263189 | Patients at high risk of invasive fungal infections: when and how to treat |
| Q36128742 | Predicting invasive fungal disease due to Candida species in non-neutropenic, critically ill, adult patients in United Kingdom critical care units. |
| Q37070069 | Prediction of invasive candidal infection in critically ill patients with severe acute pancreatitis |
| Q33974292 | Prevention, diagnosis, therapy and follow-up care of sepsis: 1st revision of S-2k guidelines of the German Sepsis Society (Deutsche Sepsis-Gesellschaft e.V. (DSG)) and the German Interdisciplinary Association of Intensive Care and Emergency Medicine |
| Q34123634 | Prior antimicrobial therapy and risk for hospital-acquired Candida glabrata and Candida krusei fungemia: a case-case-control study |
| Q35889819 | Prophylaxis and treatment of invasive candidiasis in the intensive care setting |
| Q36261766 | Prophylaxis of Candida infections in adult trauma and surgical intensive care patients: a systematic review and meta-analysis |
| Q53887873 | Prospective evaluation of the epidemiology, microbiology, and outcome of bloodstream infections in adult surgical cancer patients. |
| Q61757039 | Prävention, Diagnose, Therapie und Nachsorge der Sepsis |
| Q40052023 | Quantification of CDR1 Gene Expression in Fluconazole Resistant Candida Glabrata Strains Using Real-time PCR. |
| Q46281167 | Rapid Detection and Differentiation of Clinically Relevant Candida Species Simultaneously from Blood Culture Using A Novel Signal Amplification Approach |
| Q91522278 | Rapid Identification of Candida Species in Candidemia Directly from Blood Samples Using Imperfect Match Probes |
| Q35912243 | Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. |
| Q90436045 | Risk factors for candidemia: a prospective matched case-control study |
| Q36228988 | Risk factors for early invasive fungal disease in critically ill patients |
| Q36073057 | Risk factors for invasive fungal disease in critically ill adult patients: a systematic review |
| Q43571511 | Risk-based fluconazole prophylaxis of Candida bloodstream infection in a medical intensive care unit |
| Q34202154 | Role of sentinel surveillance of candidemia: trends in species distribution and antifungal susceptibility |
| Q53294855 | Role of the Inositol Polyphosphate Multikinase Ipk2 in Regulation of Hyphal Development, Calcium Signaling and Secretion in Candida albicans. |
| Q34042232 | Seminational surveillance of fungemia in Denmark: notably high rates of fungemia and numbers of isolates with reduced azole susceptibility. |
| Q95275804 | Sepsis and ECMO |
| Q92283137 | Septic pulmonary embolism in China: clinical features and analysis of prognostic factors for mortality in 98 cases |
| Q83630554 | Significance of the isolation of Candida species from airway samples in critically ill patients: a prospective, autopsy study |
| Q36465424 | Single-drug therapy or selective decontamination of the digestive tract as antifungal prophylaxis in critically ill patients: a systematic review. |
| Q43427231 | Six-year trend analysis of nosocomial candidemia and risk factors in two intensive care hospitals in Mato Grosso, midwest region of Brazil |
| Q35758901 | Species-specific differences in the susceptibilities of biofilms formed by Candida bloodstream isolates to echinocandin antifungals |
| Q40321242 | Spectrum of pathogens in postoperative complications of visceral surgery : The problem of multidrug resistance |
| Q34856747 | Surveillance study of species distribution, antifungal susceptibility and mortality of nosocomial candidemia in a tertiary care hospital in China |
| Q38433744 | Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. |
| Q35585219 | Systemic Antifungal Therapy: New Options, New Challenges |
| Q39990693 | The Correlation Between Candida Colonization of Distinct Body Sites and Invasive Candidiasis in Emergency Intensive Care Units: Statistical and Molecular Biological Analysis |
| Q37522581 | The Rbf1, Hfl1 and Dbp4 of Candida albicans regulate common as well as transcription factor-specific mitochondrial and other cell activities |
| Q37289366 | The damage-response framework of microbial pathogenesis and infectious diseases |
| Q36223365 | The morbidity and mortality of patients with fungal infections before and during extracorporeal membrane oxygenation support |
| Q92575287 | The potential of respiration inhibition as a new approach to combat human fungal pathogens |
| Q61965678 | The role of intravascular devices in sepsis |
| Q34480715 | The use of prophylactic fluconazole in immunocompetent high-risk surgical patients: a meta-analysis |
| Q36747533 | Time to blood culture positivity as a marker for catheter-related candidemia |
| Q45123004 | Traditional microbiological diagnosis for invasive candidiasis in critical non-neutropenic patients |
| Q38609687 | Treatment of Fungal Urinary Tract Infection |
| Q37327117 | Treatment of critically ill patients with candidemia. |
| Q37469829 | Treatment of invasive fungal infections in cancer patients-updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). |
| Q30453032 | Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000. |
| Q36898200 | Trends in species distribution and susceptibility of bloodstream isolates of Candida collected in Monterrey, Mexico, to seven antifungal agents: results of a 3-year (2004 to 2007) surveillance study |
| Q64089898 | Twenty Years of the SENTRY Antifungal Surveillance Program: Results for Species From 1997-2016 |
| Q44506237 | Use of antifungal agents in pediatric and adult high-risk areas |
| Q36070524 | Validation and comparison of clinical prediction rules for invasive candidiasis in intensive care unit patients: a matched case-control study |
| Q35179545 | Voriconazole |
| Q38203447 | What's new in the clinical and diagnostic management of invasive candidiasis in critically ill patients |
| Q46000235 | [Clinical use of micafungin for the treatment of invasive candidiasis in critical ill patients]. |
| Q83752505 | [Clinical, epidemiological and taxonomic aspects of systemic candidiasis in an intensive care unit] |
| Q82653839 | [Epidemiology of candidemia in ICU] |
| Q82653859 | [Prevention of invasive candidiasis in the critically ill non neutropenic patient] |
| Q82653853 | [Risk factors in invasive candidiasis: stratification] |
| Q45942586 | [Role of anidulafungin in critically ill patients]. |
Search more.